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Introduction: The perioperative pain experience shows great interindividual variability and is 
difficult to predict. The mu-1 opioid receptor gene (OPRM1) is known to play an important role 
in opioid-pain pathways. Since deoxyribonucleic acid (DNA) methylation is a potent repressor 
of gene expression, DNA methylation was evaluated at the OPRM1 promoter, as a predictor of 
preoperative, acute, and chronic postsurgical pain (CPSP).
Methods: A prospective observational cohort study was conducted in 133 adolescents with 
idiopathic scoliosis undergoing spine fusion under standard protocols. Data regarding pain, 
opioid consumption, anxiety, and catastrophizing (using validated questionnaires) were col-
lected before and 2–3 months postsurgery. Outcomes evaluated were preoperative pain, acute 
postoperative pain (area under curve [AUC] for pain scores over 48 hours), and CPSP (numerical 
rating scale >3/10 at 2–3 months postsurgery). Blood samples collected preoperatively were 
analyzed for DNA methylation by pyrosequencing of 22 CpG sites at the OPRM1 gene promoter. 
The association of each pain outcome with the methylation percentage of each CpG site was 
assessed using multivariable regression, adjusting for significant (P<0.05) nongenetic variables.
Results: Majority (83%) of the patients reported no pain preoperatively, while CPSP occurred 
in 36% of the subjects (44/121). Regression on dichotomized preoperative pain outcome showed 
association with methylation at six CpG sites (1, 3, 4, 9, 11, and 17) (P<0.05). Methylation at 
CpG sites 4, 17, and 18 was associated with higher AUC after adjusting for opioid consumption 
and preoperative pain score (P<0.05). After adjusting for postoperative opioid consumption and 
preoperative pain score, methylation at CpG sites 13 and 22 was associated with CPSP (P<0.05).
Discussion: Novel CPSP biomarkers were identified in an active regulatory region of the 
OPRM1 gene that binds multiple transcription factors. Inhibition of binding by DNA meth-
ylation potentially decreases the OPRM1 gene expression, leading to a decreased response to 
endogenous and exogenous opioids, and an increased pain experience.
Keywords: OPRM1, epigenetics, pain, chronic postsurgical pain, DNA methylation
Introduction
Inadequately controlled pain remains a significant problem after surgery, as it negatively 
affects quality of life and function and increases the risk of persistent postsurgical 
pain.1 Approximately 50%–75% of patients undergoing surgery experience moderate or 
severe pain, and this is true for the 6 million children who undergo surgery every year 
in the US.2,3 Chronic postsurgical pain (CPSP) is the pain that lasts beyond 2 months 
postsurgery.4 In children, the incidence of CPSP ranges from 13% to 68.8%.5,6 This 
implies that of the 1.5 million children who undergo major surgery every year in the US, 
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~225,000–1,000,000 children develop CPSP.7 Interindividual 
variability in pain sensitivity,8 acute postsurgical pain,9–11 and 
CPSP have been partly explained by genetic markers.12 The 
mu-1 opioid receptor gene (OPRM1) that codes for the mu 
opioid receptor (MOR) plays an important role in opioid-
pain pathways.13 The OPRM1 variant that has been most 
commonly studied is the A118G variant; however, the results 
of association studies with pain and β-endorphin-binding 
activity between this variant and the wild-type receptors are 
controversial.14–17
Beyond genetics, chronic pain is a classic example of 
gene–environment interaction,18 and hence recently inter-
est has been directed toward the role of epigenetics in pain. 
Epigenetics is the study of changes in chromosomes that do 
not alter the sequence of deoxyribonucleic acid (DNA),19 but 
may still lead to alterations in gene expression. Genetics and 
epigenetics together are important factors in the transition 
of acute postsurgical pain to CPSP.20,21 DNA methylation is 
a common epigenetic mechanism, which involves the addi-
tion of a methyl group to the 5′ position of a cytosine residue 
followed by a guanine residue (a CpG dinucleotide), which 
are often clustered (CpG islands) in the promoter regions of 
genes.22 DNA methylation at the OPRM1 promoter region 
regulates DNA binding of transcription factors and is a potent 
epigenetic repressor of gene transcription.23 An increase in the 
OPRM1 promoter methylation has been found to be associated 
with a decrease in protein expression of OPRM1.24 Because 
DNA methylation is reversible, there is much interest in 
understanding its association with pain, as a potential target 
for intervention. The OPRM1 DNA methylation levels have 
been found to be elevated in opioid and heroin addicts.25,26 
However, this has not been studied in relation to perioperative 
pain and CPSP. It has been hypothesized that DNA methyla-
tion at the promoter region of OPRM1 will be associated with 
pain before and after surgery. Understanding the contribution 
of OPRM1 genetic–epigenetic interactions to pain outcomes 
will allow prediction of susceptibility to poor pain control and 
CPSP and will enable target identification for modification of 
risk studies in the future.
Methods
A prospective observational cohort study was conducted 
in 133 adolescents with idiopathic scoliosis undergoing 
posterior spine fusion under standard intraoperative anes-
thesia (propofol–remifentanil total intravenous anesthesia, 
guided by electroencephalography monitoring for depth 
of anesthesia) and postoperative analgesia with morphine 
patient-controlled analgesia along with adjuvants ( scheduled 
intravenous acetaminophen, ketorolac, and diazepam as 
needed and methocarbamol) managed by perioperative pain 
team. The study was approved by the Cincinnati Children’s 
Hospital Institutional Review Board. This study is regis-
tered with ClinicalTrials.gov identifiers NCT01839461 and 
NCT01731873. Written informed consent was obtained 
from parents, and assent was obtained from children before 
enrollment.
Participants
Healthy nonobese subjects with an American Society of 
Anesthesiologists (ASA) physical status ≤2 (mild systemic 
disease), aged 10–18 years, with a diagnosis of idiopathic sco-
liosis and/or kyphosis, and undergoing elective spinal fusion 
were recruited. The exclusion criteria included pregnant or 
breastfeeding females, presence of chronic pain defined as 
use of opioids in the past 6 months, liver or renal diseases, 
and developmental delays.
Data collection
Preoperatively, data regarding demographic factors (sex, 
age, and race), weight, pain scores (numerical rating scale 
[NRS]/0–10)27 on the day of surgery (P0), and pain medi-
cations used were obtained. Anxiety scores for both child 
and a parent were assessed using the 0–10 visual analog 
scale (VAS), a simple validated scale that has been used 
previously in children.28 Questionnaires were administered 
as described in the following sections. The intraoperative 
data collected included propofol and remifentanil doses, 
duration of surgery, and number of vertebral levels fused. 
In the immediate postoperative period (postoperative days 
[PODs] 1 and 2), pain scores (every 4 hours) and morphine 
and diazepam doses administered were noted. After hospital 
discharge, the questionnaires were administered per schedule 
presented in Table 1 to obtain psychosocial and pain measures 
in a standard fashion.
Outcomes
Pain outcomes evaluated were 1) preoperative pain, 2) acute 
postoperative pain (defined as area under curve [AUC] for 
pain scores over time on POD 1 and 2 [AUC
POD1–2
] calculated 
using trapezoidal rule), and 3) chronic pain/CPSP (NRS 
>3/10 at 2–3 months postsurgery) as defined by the Inter-
national Association for the Study of Pain.29 These cut offs 
for NRS were used because NRS pain scores >3 (moderate/
severe pain) at 3 months have been described as a predic-
tor for persistence of pain and associated with functional 
disability.30
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Measurement of DNA methylation
Blood was drawn upon intravenous line placement before 
surgery, from which the DNA was isolated on the same day 
and frozen at –20°C. To study DNA methylation, the focus 
was on a 251 bp region, including 22 CpG sites reaching 
from position –93 to position +159, whose methylation levels 
were previously shown to be associated with the OPRM1 
expression24 and opioid/heroin addiction (Figure 1).25,26 The 
CpG sites are numbered according to those studies25,26 to 
allow for an easy comparison. This included a CpG site at 
+117, reported by Oertel et al.24 The pyrosequencing assays 
utilize 50–500 ng of genomic DNA of acceptable quality 
(measured by Thermo Scientific NanoDrop spectrophotom-
eter [Waltham, MA, USA] and with a 260/280 ratio rang-
ing from 1.6 to 2.0). The extracted DNA was treated with 
bisulfite using Zymo EZ DNA Methylation Gold Kit (Zymo 
Research, Orange, CA, USA), according to the manufac-
turer’s instructions. Two sets of primers, long and nested, 
were designed using ZymoTaq Premix (Zymo Research) for 
two rounds of polymerase chain reaction (PCR). Methylation 
of the PCR products was quantified using PyroMark MD 
1.0 software (Qiagen, Valencia, CA, USA). Primers used 
in the assays are listed in Table 2. Samples were repeated if 
the pyrosequencing runs did not pass quality checks of the 
pyrosequencer or if the internal bisulfite conversion controls 
failed. The sample runs were monitored through methylated 
and nonmethylated DNA as well as template-free negative 
controls.
Data analysis
Prior to the analyses, the data quality was assessed. 
Demographics and patients’ clinical characteristics were 
 summarized as mean (standard deviation [SD]), median, 
and frequency (percentage) according to the distribution of 
the data. Prior to evaluation of the association between pain 
outcome and DNA methylation, the effects of covariables 
were tested, which included age, sex, race, morphine dose 
in mg/kg on POD 1 and 2, preoperative anxiety score (VAS), 
preoperative pain score, duration of surgery, vertebral levels 
fused, propofol and remifentanil doses used during surgery 
(per kg), use of intravenous acetaminophen/ketorolac (yes/
no), diazepam doses (mg/kg), and pain catastrophizing scale 
(parent version) and parent pain history scores and sequential 
scores for Childhood Anxiety Sensitivity Index and pain cata-
strophizing scale (child version).31 Three pain outcomes were 
examined. Preoperative pain was dichotomized as yes versus 
no, because, although it was measured using NRS as a 0–10 
scale, 83% of the patients reported no preoperative pain. It 
was then associated with covariables using logistic regression. 
Similarly, acute postoperative pain was analyzed using simple 
linear regression models, and CPSP using  logistic regres-
sion models. Covariables associated at P<0.10 were entered 
into multivariable models, and stepwise selection was used 
to derive a final nongenetic model for each outcome where 
only variables with P<0.05 were retained.32 DNA methylation 
levels were then added to the final nongenetic model to assess 
their association with the pain outcomes. Statistical analyses 
Table 1 Data collection schema
Data variables Preoperative Intraoperative Over 48 hours  
after surgery
2–3 months
Demographics
Anxiety score
x
Surgical duration
Vertebral levels fused
Propofol dose
Remifentanil dose
x
Pain scores
Opioid consumption
Diazepam use
Analgesic adjuncts
x x x
Child questionnaires
CASI
PCS-C
FDI
Pain assessment
x x
Parent questionnaires
PPH
PCS-P
x
Notes: Time calculated from end of surgery. x indicates the phase in which the data is collected.
Abbreviations: CASI, Childhood Anxiety Sensitivity Index; FDI, Functional Disability Index; PCS-C, pain catastrophizing scale (child version); PCS-P, pain catastrophizing 
scale (parent version); PPH, parent pain history.
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were performed using Statistical Analysis System, version 
9.3 (SAS Institute Inc., Cary, NC, USA). P≤0.05 was used as 
the threshold for statistical significance. No multiple testing 
correction was done, thus it is possible that some findings 
occurred by chance.
Functional genomics analysis
To identify potential regulatory mechanisms in the OPRM1 
promoter, a large collection of functional genomics data 
sets from various sources, including ENCODE,33 Road-
map  Epigenomics,34 Cistrome,35 and ReMap-ChIP, was 
compiled.36 The genomic coordinates of the OPRM1 pro-
moter were intersected against the genomic coordinates 
contained in each data set. In total, this database contains 
4,953 data sets performed in 1,706 different cell types and 
conditions; 1,911 data sets monitor binding interactions 
of transcription factors with the human genome using 
ChIP-seq; 1,214 measure the presence of a particular his-
tone mark using ChIP-seq; 226 measure open chromatin 
through DNase-seq; 57 measure expression quantitative 
trait loci (eQTLs); and 558 predict “ActiveChromatin” 
states using combinations of histone marks.37 Collectively, 
240 of these experiments were performed in brain-related 
cell lines and cell types.
Results
The final cohort comprised 133 participants; the mean age 
was 14.49 years (SD 1.91), and they were mostly white 
(83%) and female (74%) (Table 3). The recruitment timeline 
is described in Figure 2. Descriptions of variables that were 
evaluated for inclusion in the multiple regression model are 
presented in Table 3.
Pain descriptives
Acute and chronic postoperative pain data were collected for 
128 and 121 patients, respectively. The overall incidence of 
CPSP was found to be 36.4% (44/121). The preoperative pain 
score was 0 in 83% (106/127) of the cohort.
Figure 1 Depiction of the OPRM1 promoter region (HG19; Chr 6: 154360587 to 154360838) and the location of the CpG sites. The knobs represent each CpG site, and 
the primers are indicated in brackets below. The red-colored knob at +117 indicates the CpG site (CpG17) associated with the variant A118G. The arrows indicate sites 
that have been described as Sp1 transcription factor-binding sites in previous studies (CpG sites 9, 10, 12, 16, 21, and 23 at –18, –14, 12, +84, +145, +150, and +159 from 
ATG site).
Abbreviations: OPRM1, mu-1 opioid receptor gene; TSS, transcription start site.
S1/NF_CpG1–7
CHR6: 154360587
–93 from TSS
CHR6: 154360838
+159 from TSS
CpG1
3 10 bp 11 bp 10 18 7 7 4 4 21 bp 57 bp 33 9 9 5 5 5 911 4
TSS for isoform 2
OPRM1 gene promoter region
9 bp
Sp1 transcription sites (Oertel et al24)
Sp1 transcription sites (Nielsen et al26)
A>G at this site may create a CpG site
Primers and
CpG sites S2_CpG8–14 S4_CpG18–23
S3_CpG16–17
Table 2 Primers used in the pyrosequencing assay
Primer Forward CpG sites
OPRM1_NF 5′- TAAGAAATAGTAGGAGTTGTGGTAG -3′
OPRM1_NR 5′-Biotin-AAAAACACAAACTATCTCTCCC -3′
OPRM1_LF 5′- TGTAAGAAATAGTAGGAGTTGTGGTAG -3′
OPRM1_LR 5′- AAATAAAACAAATTAACCCAAAAAC -3′
OPRM1_S1/NF 5′-TAAGAAATAGTAGGAGTTGTGGTAG-3′ CpG1–7
OPRM1_S2 5′-GGTGTTTTTGGTTATTTGGTATAG-3′ CpG8–14
OPRM1_S3 5′-GTATTTAAGTTGTTTTTTAGTATTTAG-3′ CpG 16 and 17 (SNP-CpG)
OPRM1_S4 5′-GGGTTAATTTGTTTTATTTAGATGGT-3′ CpG18–22
Note: LF and LR: forward and reverse primers used in the first round, long PCR; NF and NR: forward and reverse primers used in the second round, nested PCR.
Abbreviations: OPRM1, mu-1 opioid receptor gene; PCR, polymerase chain reaction.
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DNA methylation and pain
Three pain outcomes were examined. For the association with 
dichotomized preoperative pain scores, logistic regression 
was used. After adjusting for age and sex, the methylation 
level of six CpG sites (sites 1, 3, 4, 9, 11, and 17, Table 4) 
was significantly associated with whether a patient reported 
preoperative pain. For all the six CpG sites, higher methyla-
tion was associated with higher odds of reporting preopera-
tive pain, except for site 17. No impact of the methylation 
on the actual pain scores was detected (data not shown). For 
acute postoperative pain (AUC
POD1–2
), significant impact of 
methylation was detected in CpG sites 4, 17, and 18 (Table 4) 
when preoperative pain and morphine consumption were 
adjusted. For all three CpG sites, higher methylation was 
associated with higher preoperative pain. For chronic post-
operative pain, significant association was detected for the 
nonpromoter site, CpG13 and 22 (Table 4), with preoperative 
pain and morphine consumption being controlled. For all the 
CpG sites, higher methylation was associated with higher 
odds of having chronic pain. Methylation at two CpG sites 
was associated with both preoperative pain and AUC
POD1–2
 
(CpG 4 and 17); methylation at these sites also showed a 
trend toward CPSP risk, although not statistically significant. 
Figure 3 depicts estimated probabilities of developing CPSP 
using median preoperative pain score (0), median morphine 
doses (1.7 mg/kg), and 2.5th, 25th, 50th, 75th and 97.5th 
percentiles of the methylation data of each of the two sites 
CpG13 and CpG22.
Functional genomics analysis
Query of the region evaluated using a large collection of 
ChIP-seq, DNase-seq, and eQTL data, as described in the 
“Methods” section, showed that this region is located in 
open chromatin and is marked by H3K27ac, H3K4me1, and 
H3K4me3 (indicative of active regulatory regions)38–40 in 
noncancer brain cells from the caudate–putamen, temporal, 
frontal lobes, and angular gyri. Moreover, this region con-
tains ChIP-seq peaks for binding of multiple transcription 
factors, including REST, RAD21, SP1, YY1, and ZNF263 
in various tissues. In particular, REST and RAD21 bind 
the OPRM1 promoter region in three cell lines (SK-N-SH, 
PFSK-1, and SK-N-SH) derived from brain tissue where the 
opioid receptors responsible for analgesia are found (Table 5). 
Collectively, these results suggest that the differential DNA 
methylation patterns observed in the OPRM1 promoter might 
functionally act by modulating the expression of OPRM1 via 
alteration of the binding of REST and other neuron-expressed 
transcription factors.
Discussion
It has been previously shown that psychological and clinical 
variables contribute to CPSP.31 This study finds associations 
between epigenetics and CPSP in children for the first time 
and adds to the emerging evidence linking epigenetic mecha-
nisms to the development of chronic pain states.41 Specifi-
cally, it was found that novel biomarkers (DNA methylation of 
certain CpG sites in the OPRM1 promoter region) associated 
Table 3 Demographics of the cohorts and description of the covariates used in the regression model
Variable Acute postoperative pain (N=128) CPSP
P-valued No (N=77) Yes (N=44) P-value
Agea (years) 14.49 ± 1.91 0.15 14.20 ± 1.87 14.78 ± 1.67 0.10
Sexb 0.23 0.54
Male 35 (26%) 20 (26%) 9 (21%)
Raceb 0.21 0.13
White 111 (83%) 66 (86%) 32 (74%)
Weightc (kg) 54.00 (48.00–61.90) 0.83 54.20 (48.00–61.9) 54.00 (50.00–61.00) 0.90
VAS anxietyc (child) 4.30 (2.50–6.80) 0.24 4.40 (2.60–6.80) 3.60 (1.80–5.20) 0.39
VAS anxietyc (parent) 5.50 (4.36–8.00) 0.24 5.40 (4.60–8.00) 5.90 (4.40–8.10) 0.94
Preoperative pain scorec 0.00 (0.00–0.00) <0.001 0.00 (0.00–0.00) 0.00 (0.00–2.00) 0.015
Number of vertebral levels fusedc 12.00 (11.00–12.00) 0.58 12.00 (11.00–12.00) 12.00 (10.00–12.00) 0.91
Surgical duration (hours)a 4.91 ± 1.27 0.21 4.71 ± 1.07 5.09 ± 1.45 0.14
Pain AUCPOD1–2
a 198.58 ± 73.78 – 189.04 ± 67.61 222.64 ± 80.44 0.018
Morphine dose POD1 & 2c (mg/kg) 1.60 (1.19–2.17) 0.15 1.59 (1.08–1.93) 1.89 (1.50–2.47) 0.003
CASIa 28.21 ± 5.87 0.18 27.86 ± 5.99 28.38 ± 5.80 0.71
Notes: aData exhibited normal distribution, shown as mean ± SD and compared using t-tests for CPSP. bShown as frequency (proportion) and compared using chi-squared 
tests for CPSP. cData did not exhibit a normal distribution, shown as median (IQR) and compared using Wilcoxon rank-sum tests for CPSP. dAssessed using Spearman’s rank 
correlation.
Abbreviations: AUC, area under curve; CASI, Child Anxiety Sensitivity Index; CPSP, chronic postsurgical pain; IQR, interquartile range; POD, postoperative day; SD, 
standard deviation; VAS, visual analog scale.
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with preoperative pain, acute postoperative pain, and CPSP 
following posterior spine fusion in healthy adolescents. DNA 
methylation was also associated with pain before surgical 
stimulus and exposure to opioids. These findings allow for 
prediction of risk for the pain response to surgery and pos-
sible novel mechanisms that could be targeted for prevention 
and treatment of CPSP.
Endogenous opioid peptides and exogenously administered 
opioid analgesics bind to MOR to regulate pain responses. 
The MOR activity is regulated at different levels, including 
epigenetic mechanisms.23 Many of the CpG sites found to be 
associated with pain outcomes (1, 3, 4, 9, 11, 13, 17, 18, and 
22) have been previously described as putative Sp1 transcrip-
tion factor-binding sites. These include CpG sites 9, 10, 12, 
16, 21, and 23 at –18, –14, 12, +84, +145, and +159 from ATG 
site, respectively.26 Methylation levels at some of these sites 
were previously found to be associated with opioid addiction/
dependence. Nielsen et al found that CpG sites at –18 and +84 
(9 and 16) were more strongly methylated in heroin addicts 
than controls. Similarly, seven CpG sites showed significant 
hypermethylation of blood DNA taken from male opioid 
addicts when compared to blood DNA from controls (CpGs 
5, 9, 10, 11, 18, and 23).26 Increased methylation within the 
OPRM1 promoter (at –14, –10 [sites 10, 11]) was also found 
to be associated with worse neonatal abstinence syndrome 
outcomes in infants exposed to opioids in utero.42 It has been 
shown in mouse brain tissues that DNA methylation of the 
OPRM1 promoter decreases expression of the gene; through 
interaction with chromatin-remodeling factors, remodeling 
occurs, thus allowing access for Sp1 binding,43 which results 
in the MOR upregulation. Thus, methylation at these sites can 
prevent the OPRM1 activation, leading to decreased endog-
enous and exogenous opioid effects, manifested in the experi-
ence of increased perioperative pain. In addition, Chorbov et 
al also observed increased DNA methylation in the sperm of 
addicts, which may suggest a means of epigenetic heritability 
of opioid phenotypes.25
Animal studies have shown that OPRM1 promoter meth-
ylation reduced OPRM1 expression.23 Knothe et al confirmed 
methylation effects on OPRM1 expression through experi-
ments in human cell lines (neuronal SHSY5Y and Kelly, and 
nonneuronal HEK-293) with and without the demethylating 
Figure 2 Recruitment timeline for the spine surgery study cohort is delineated. Of the 261 eligible patients who satisfied the inclusion/exclusion criteria, reasons for not 
enrolling and derivation of final cohorts included in the study with preoperative, acute, and chronic pain outcomes are described.
261 eligible/approached participants
133 participants enrolled
128 participants completed the perioperative protocols
128 participants included for acute pain
outcomes
127 participants for preoperative
pain outcome
121 participants for chronic
pain outcomes 
Declined (n=90)
Repeat/other surgeries
within 2–3 months (n=1)
No follow-up at 2–3
months (n=6)
Chronic pain outcome
exclusions (n=7)
Reason and number not recruited (n=128)
Preoperative pain outcome
exclusion (n=1)
No preoperative pain recorded (n=1)
Study staff unavailable (n=20)
Enrolled in another study (n=9)
Patient late – no time to consent (n=4)
Case canceled (n=5)
Withdrawal (n=5) due to remaining intubated
postoperative delays, cancelations, and
complications
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Table 4 Association of DNA methylation of CpG sites at the OPRM1 promoter with pain outcomes
CpG site* Location Genomic 
location
Preoperative pain  
score of 1a
Acute painb CPSPc 
P-value Regression 
coefficient
P-value Regression 
coefficient
P-value Regression 
coefficient
OR (95% CI)
1 –93 154360587 0.023 0.051 0.290 0.620 0.189 –0.028 0.972 (0.932–1.015)
2 –90 154360590 0.256 0.023 0.464 0.396 0.452 0.014 1.014 (0.978–1.053)
3 –80 154360600 0.035 0.041 0.153 0.772 0.368 –0.017 0.983 (0.946–1.021)
4 –71 154360609 0.026 0.054 0.003 1.864 0.995 0.000 1.000 (0.957–1.046)
5 –60 154360620 0.916 –0.003 0.495 0.412 0.411 0.017 1.017 (0.977–1.060)
6 –50 154360630 0.589 0.009 0.100 0.836 0.731 0.006 1.006 (0.973–1.040)
7 –32 154360648 0.145 0.019 0.221 0.466 0.567 0.007 1.007 (0.983–1.033)
8 –25 154360655 0.198 0.021 0.875 –0.070 0.227 0.019 1.019 (0.988–1.050)
9
−18 154360662 0.020 0.038 0.925 0.044 0.548 0.010 1.010 (0.978–1.043)
10
−14 154360666 0.979 0.001 0.886 –0.097 0.893 0.003 1.003 (0.958–1.051)
11
−10 154360670 0.008 0.049 0.443 0.404 0.147 0.029 1.029 (0.989–1.071)
12 12 154360691 0.716 0.013 0.500 0.625 0.117 0.051 1.052 (0.985–1.124)
13 23 154360702 0.305 0.018 0.460 0.356 0.002 0.067 1.069 (1.022–1.119)
14 27 154360706 0.810 –0.006 0.444 0.441 0.793 0.006 1.006 (0.964–1.049)
16 84 154360763 0.221 0.069 0.730 0.512 0.150 0.073 1.075 (0.973–1.188)
17 118 154360796 0.029 –0.997 0.034 17.736 0.114 0.516 1.675 (0.885–3.171)
18 126 154360805 0.205 0.019 0.031 0.921 0.804 0.004 1.004 (0.975–1.033)
19 135 154360814 0.334 0.019 0.415 0.418 0.856 –0.003 0.997 (0.962–1.033)
20 140 154360819 0.151 0.025 0.826 0.108 0.977 –0.001 1.000 (0.966–1.034)
21 145 154360824 0.103 0.029 0.914 0.053 0.861 0.003 1.003 (0.970–1.038)
22 150 154360829 0.446 0.014 0.314 0.497 0.046 0.036 1.037 (1.000–1.075)
23 159 154360838 0.491 0.023 0.385 0.750 0.480 0.022 1.022 (0.964–1.083)
Notes: *CpG sites are numbered the same as in other studies for ease of comparison. aModeled using logistic regression on the probability of preoperative pain =1. Age and 
sex were controlled. Results shown represent the change of log OR with 1% increase in DNA methylation. bModeled using linear regression adjusted for preoperative pain 
score and morphine consumption over postoperative days 1 and 2. cModeled using logistic regression adjusted for preoperative pain score and morphine consumption over 
postoperative days 1 and 2. OR represents the odds of CPSP with 1% increase in the DNA methylation level. P<0.05 are presented in bold.
Abbreviations: CI, confidence interval; CPSP, chronic postsurgical pain; OPRM1, mu-1 opioid receptor gene; OR, odds ratio.
Figure 3 The probability of developing CPSP based on DNA methylation at CpG 
13 and 22, derived from the regression model, is depicted. The probabilities were 
estimated using median preoperative pain scores (0), median morphine consumption 
(1.7 mg/kg), and 2.5%, 25%, 50%, 75%, and 97.5% of the methylation data of each 
of the two sites. The 97.5% values for DNA methylation in the data are 40% for 
CpG13 and 57% for CpG22. The nongenetic covariates are already adjusted for 
in the regression model. Hence, the probability of CPSP holding other variables 
constant increases with increased methylation at these sites.
Abbreviation: CPSP, chronic postsurgical pain.
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agent 5′-aza-2′-deoxycytidine.44 But they did not find that 
methylation profiles across the OPRM1 gene from CpG 
position –93 to +159 in brain tissues collected postmortem 
from heroin addicts correlated with differences in OPRM1 
mRNA expression in the corresponding brain regions.44 
Opioid exposure in all their subjects may have played a role 
in minimizing methylation differences between the speci-
mens and the individuals. Hence, the lack of correlation in 
their study does not rule out the differences that may exist 
between opioid-exposed and nonopioid-exposed (or pain vs 
no pain) subjects.
The findings of this study corroborate a growing body 
of evidence that OPRM1 DNA methylation affects pain 
behaviors and contributes to the limited efficacy of opi-
ates in certain cases,45 which is improved upon blockade 
of methylation.46 In a neuropathic animal model, it was 
shown that increased methylation of the MOR gene proxi-
mal promoter in dorsal root ganglion decreased morphine 
analgesia.47 Administration of demethylating agents reversed 
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Data set name Type Cell-type label Cell-type group Chromosome 6
Start End
ENCODE_ChIP-seq REST PFSK-1 Neuron 154360476 154360892
ENCODE_ChIP-seq REST SK-N-SH Neuron 154360476 154360892
ENCODE_ChIP-seq REST U87 Glial_cell 154360476 154360892
ENCODE_ChIP-seq RAD21 SK-N-SH_RA Neuron 154360485 154360774
ENCODE_DNase-seq DNase Cerebellum_OC Cerebellum 154360055 154361686
ENCODE_DNase-seq DNase SK-N-SH Neuron 154360205 154361641
ENCODE_DNase-seq DNase Medullo Neuron 154360485 154360635
ENCODE_DNase-seq DNase Medullo_D341 Neuron 154360500 154360704
ENCODE_DNase-seq DNase BE2_C Neuroblast 154360520 154360670
ENCODE_DNase-seq DNase SK-N-MC Neuron 154360560 154360710
ENCODE_DNase-seq DNase HA-h Glial_cell 154360580 154360730
ENCODE_DNase-seq DNase HAc Glial_cell 154360620 154360770
ENCODE_DNase-seq DNase SK-N-SH_RA Neuron 154360660 154360810
Roadmapepigenomics_ActiveChromatin 10_TssBiv Brain_Germinal_Matrix Germinal_matrix 154360200 154361000
Roadmapepigenomics_ActiveChromatin 10_TssBiv Brain_Inferior_Temporal_Lobe Temporal_lobe 154360200 154361000
Roadmapepigenomics_ActiveChromatin 2_TssAFlnk Neurosphere_Ganglionic_Eminence_
Derived
Neurosphere 154360200 154360600
Roadmapepigenomics_ActiveChromatin 10_TssBiv Brain_Angular_Gyrus Angular_gyrus 154360400 154361200
Roadmapepigenomics_ActiveChromatin 10_TssBiv Brain_Anterior_Caudate Caudate–putamen 154360400 154361200
Roadmapepigenomics_ActiveChromatin 10_TssBiv Brain_Cingulate_Gyrus Cingulate_gyrus 154360400 154361800
Roadmapepigenomics_ActiveChromatin 10_TssBiv Brain_Dorsolateral_Prefrontal_Cortex Prefrontal_cortex 154360400 154361800
Roadmapepigenomics_ActiveChromatin 2_TssAFlnk Neurosphere_Cortex_Derived Neurosphere 154360400 154361000
Roadmapepigenomics_ActiveChromatin 1_TssA Neurosphere_Ganglionic_Eminence_
Derived
Neurosphere 154360600 154360800
Roadmapepigenomics_ActiveChromatin 2_TssAFlnk Neurosphere_Ganglionic_Eminence_
Derived
Neurosphere 154360800 154361000
Roadmapepigenomics_HistoneMarks H3K27me3 Brain_Germinal_Matrix Germinal_matrix 154359832 154361779
Roadmapepigenomics_HistoneMarks H3K27me3 Brain_Cingulate_Gyrus Cingulate_gyrus 154359959 154360615
Roadmapepigenomics_HistoneMarks H3K4me3 Brain_Inferior_Temporal_Lobe Temporal_lobe 154360134 154361957
Roadmapepigenomics_HistoneMarks H3K4me3 Neurosphere_Cultured_Cells_
Ganglionic_Eminence_Derived
Neurosphere 154360141 154361032
Roadmapepigenomics_HistoneMarks H3K4me3 Brain_Anterior_Caudate Caudate–putamen 154360158 154361200
Roadmapepigenomics_HistoneMarks H3K27ac Brain_Anterior_Caudate Caudate–putamen 154360161 154361089
Roadmapepigenomics_HistoneMarks H3K27me3 Brain_Hippocampus_Middle Hippocampus 154360219 154361820
Roadmapepigenomics_HistoneMarks H3K9ac Brain_Anterior_Caudate Caudate–putamen 154360231 154360919
Roadmapepigenomics_HistoneMarks H3K4me3 Neurosphere_Cultured_Cells_Cortex_
Derived
Neurosphere 154360232 154360613
Roadmapepigenomics_HistoneMarks H3K4me3 Brain_Germinal_Matrix Germinal_matrix 154360236 154361028
Roadmapepigenomics_HistoneMarks H3K4me3 Brain_Angular_Gyrus Angular_gyrus 154360273 154361216
Roadmapepigenomics_HistoneMarks H3K27me3 Brain_Angular_Gyrus Angular_gyrus 154360276 154361392
Roadmapepigenomics_HistoneMarks H3K27ac Brain_Mid_Frontal_Lobe Frontal_lobe 154360280 154360645
Roadmapepigenomics_HistoneMarks H3K4me3 Brain_Cingulate_Gyrus Cingulate_gyrus 154360289 154361329
Roadmapepigenomics_HistoneMarks H3K27me3 Brain_Mid_Frontal_Lobe Frontal_lobe 154360308 154360649
Roadmapepigenomics_HistoneMarks H3K27me3 Brain_Anterior_Caudate Caudate–putamen 154360363 154361164
Roadmapepigenomics_HistoneMarks H3K9ac Brain_Mid_Frontal_Lobe Frontal_lobe 154360541 154360711
Roadmapepigenomics_HistoneMarks H3K27me3 Brain_Substantia_Nigra Substantia_nigra 154360548 154361656
Roadmapepigenomics_HistoneMarks H3K27ac Brain_Inferior_Temporal_Lobe Temporal_lobe 154360556 154361011
Roadmapepigenomics_HistoneMarks H3K4me3 Brain_Mid_Frontal_Lobe Frontal_lobe 154360586 154361813
Roadmapepigenomics_HistoneMarks H3K27me3 Brain_Inferior_Temporal_Lobe Temporal_lobe 154360592 154360975
Roadmapepigenomics_HistoneMarks H3K9ac Brain_Cingulate_Gyrus Cingulate_gyrus 154360645 154360850
Roadmapepigenomics_HistoneMarks H3K4me1 Brain_Angular_Gyrus Angular_gyrus 154360648 154360925
Roadmapepigenomics_HistoneMarks H3K9ac Brain_Angular_Gyrus Angular_gyrus 154360654 154360843
Roadmapepigenomics_HistoneMarks H3K4me1 Neurosphere_Cultured_Cells_Cortex_
Derived
Neurosphere 154360679 154361066
Roadmapepigenomics_HistoneMarks H3K9ac Brain_Inferior_Temporal_Lobe Temporal_lobe 154360694 154360980
(Continued)
Table 5 Findings from evaluation of OPRM1 promoter region using functional genomics datasets in neuronal cell-type
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the  hypermethylation of the OPRM1 gene and improved the 
analgesic effect of morphine in mice pain models.47,48 It is 
not clear if pain is the trigger or the consequence of increased 
methylation of the OPRM1 promoter. In fact, chronic opioid 
use in methadone-substituted former opiate addicts was 
found to be associated with increased DNA methylation 
at the OPRM1 position +126 (CpG 18), correlating with 
increased pain, compared to controls with pain not treated 
with opioids.49 The authors note that causal relationships with 
opioid use could not be established, as there was no opioid 
dose dependency. In their discussion, they mentioned that the 
trigger for increased methylation may actually be the baseline 
increased pain.50 This might partly explain the association 
of OPRM1 methylation with baseline pain identified in this 
study, as MOR function is essential for endogenous opioid 
action even in the absence of opioids. Useful information 
would be gained by evaluating DNA methylation changes 
over time in those who do and do not develop CPSP, in the 
presence/absence of opioids.
Although the exact mechanisms by which DNA methyla-
tion of OPRM1 promoter region contributes to pain are not 
known, the computational analysis revealed a DNA region 
bound by the repressor element 1 silencing transcription 
factor (REST) in multiple neuronal cell lines at the OPRM1 
promoter region (Table 5). Intriguingly, REST has previously 
been implicated in OPRM1 gene silencing via epigenetic 
modifications.51 REST, a member of the zinc finger transcrip-
tion factor family, represses transcription of neural genes52 in 
nonneuronal cells by binding a DNA sequence element called 
the neuron-restrictive silencer element53 and recruiting sev-
eral chromatin-modifying enzymes.54 There is also evidence 
for the involvement of REST in chronic neuropathy.52 Nerve 
injury results in a long-lasting increase in REST expression in 
mouse dorsal root ganglia.55 Hence, it is hypothesized that, in 
patients with already suppressed OPRM1 expression due to 
DNA methylation of the OPRM1 promoter, increased REST 
expression after injury possibly leads to further OPRM1 
gene silencing and worsens the pain experience. If true, this 
mechanism could potentially create new avenues for pain 
therapy. Besides the sequence-specific REST, RAD21 was 
another transcription factor that was found to be relevant 
in neuronal cells for the OPRM1 promoter region. REST is 
involved in three-dimensional DNA organization. Recent 
research, using ChIP-seq and RNA-seq data from matching 
cell types from the human ENCODE resource, showed that 
RAD21 mostly functions as an activator of transcription.56 
Although not known to play a role in OPRM1 regulation or 
pain, DNA methylation preventing binding of an activating 
transcription factor may also be responsible for decreased 
OPRM1 function and hence pain in these patients.
This study has a few limitations, one of which is the use 
of blood samples for DNA methylation, instead of target 
tissue like brain, which are understandably inaccessible in 
clinical human studies. However, this approach has been 
employed successfully before.25,26,42 Fan and Zhang compared 
methylation profiles of human chromosome 6 (OPRM1 gene 
location), derived from 12 tissues, and reported that CpG 
island methylation profiles were highly correlated between 
somatic tissues.57 Davies et al found that some interindividual 
variation in DNA methylation was reflected across brain and 
blood, indicating that peripheral tissues may have utility in 
studies of complex neurobiological phenotypes.58
In summary, we report novel associations of DNA 
methylation in the OPRM1 promoter with preoperative, 
acute, and CPSP in children undergoing spine surgery. 
Since DNA methylation is influenced by multiple modifi-
able factors (diet, exercise, parental upbringing, and stress), 
understanding the role of epigenetic regulation of OPRM1 
in pain opens new avenues of pain research. Understanding 
susceptibility may act as a guide for targeted use of aggressive 
multimodal analgesia, use of calcium-channel modulators 
(like gabapentin) and preemptive analgesics like N-methyl-
D-aspartate receptor antagonists (like ketamine), regional 
anesthesia, and behavioral therapies in patients with higher 
Data set name Type Cell-type label Cell-type group Chromosome 6
Start End
Roadmapepigenomics_HistoneMarks H3K4me3 Neurosphere_Cultured_Cells_Cortex_
Derived
Neurosphere 154360717 154360925
Roadmapepigenomics_HistoneMarks H3K4me1 Neurosphere_Cultured_Cells_
Ganglionic_Eminence_Derived
Neurosphere 154360784 154361032
Roadmapepigenomics_HistoneMarks H3K27ac Brain_Mid_Frontal_Lobe Frontal_lobe 154360822 154361016
UMMSBrain_H3K4me3 H3K4me3 Brain_prefrontal_cortex Prefrontal_cortex 154360073 154362028
Notes: Chromatin-state learning markers based on a Core 15-state model (ChromHMM), which captures key interactions between the core set of five chromatin 
marks assayed in all epigenomes (H3K4me3, H3K4me1, H3K36me3, H3K27me3, and H3K9me3). H3K4me3, H3K27ac, H3K4me1, and H3K9ac are histone modifications 
characteristic of actively transcribed promoter regions, while H3K27me3 is involved in repression of transcription.
Abbreviations: TSS, transcription start site; 1TssA, active TSS; 2TssAFlnk, flanking active TSS; 10TssBiv, bivalent, poised TSS; 11BivFlnk, flanking bivalent TSS enhancer.
Table 5 (Continued)
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risk.59 Addressing this higher risk using alternative strategies 
may be especially important as the MOR protein encoded by 
OPRM1 plays a key role in mediating not only pain responses 
but also the development of tolerance and physical depen-
dence.60,61 Future studies need to map methylation changes 
in the OPRM1 promoter over the time course of CPSP, and 
the effect of preventive and therapeutic strategies on transi-
tion of acute pain to CPSP, and development of tolerance/
opioid hyperalgesia.
Summary
Surgery is a stressful and painful experience; however, some 
individuals continue to experience pain, even months or years 
after surgery. This is because pain experience is unique. It has 
been shown that psychological factors play a role in shaping 
pain responses after surgery. Genes also play an important 
role in determining pain. One such gene is the mu-1 opioid 
receptor gene (OPRM1) that codes for the mu opioid recep-
tor (MOR), where potent pain medications (opioids) bind. 
In this study, we evaluated whether nonstructural changes 
in the deoxyribonucleic acid (DNA) (DNA methylation) of 
the regulatory region of the OPRM1 gene could predict the 
individual pain experience. In 133 adolescents undergoing 
spine fusion, after controlling for important nongenetic 
covariates identified from a previous analysis, it was found 
that methylation at several regulatory sites was associated 
with preoperative, immediate postoperative, and chronic 
postoperative pain. These sites were identified as binding 
regions for important transcription factors; methylation likely 
affects factor binding and decreases the OPRM1 expres-
sion, leading to increased pain sensitivity. These serve as 
novel biomarkers for pain and, since DNA methylation is 
modifiable, might provide a basis for future preventive and 
therapeutic strategies.
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